Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai (2024). Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer discovery, 14(8), pp. 1389-1402. American Association for Cancer Research 10.1158/2159-8290.CD-23-1334
|
Text
cd-23-1334.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview |
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC) who had received prior immunotherapy and progressed on their most recent therapy. The median number of prior systemic therapies was 2 (range, 1-6). Lifileucel was successfully manufactured using tumor tissue from different anatomic sites, predominantly lung. The objective response rate was 21.4% (6/28). Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1-negative, low tumor mutational burden, and STK11 mutation. Two responses were ongoing at the time of data cutoff, including one complete metabolic response in a PD-L1-negative tumor. Adverse events were generally as expected and manageable. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Häfliger, Simon |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2159-8290 |
Publisher: |
American Association for Cancer Research |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
04 Apr 2024 13:55 |
Last Modified: |
03 Aug 2024 00:13 |
Publisher DOI: |
10.1158/2159-8290.CD-23-1334 |
PubMed ID: |
38563600 |
BORIS DOI: |
10.48350/195558 |
URI: |
https://boris.unibe.ch/id/eprint/195558 |
Actions (login required)
 |
Edit item |